J
John H. McConville
Researcher at University of Maryland, Baltimore
Publications - 7
Citations - 171
John H. McConville is an academic researcher from University of Maryland, Baltimore. The author has contributed to research in topics: Trimethoprim & Tuberculosis. The author has an hindex of 5, co-authored 7 publications receiving 170 citations.
Papers
More filters
Journal ArticleDOI
An Outbreak of Herpes Simplex Virus Type I Gingivostomatitis in a Dental Hygiene Practice
John P. Manzella,John H. McConville,William M. Valenti,Marilyn A. Menegus,Ella M. Swierkosz,Max Arens +5 more
TL;DR: An outbreak of herpes simplex virus (HSV) type I gingivostomatitis occurred in a dental hygiene practice in November 1981 and an epidemiologic investigation disclosed that 20 of 46 patients seen by the dental hygienist during a four-day period had this illness, whereas none of 26 patients seenBy the dentist alone became ill.
Journal ArticleDOI
A Double-Blind Study of Trimethoprim-Sulfamethoxazole Prophylaxis in Patients Having Transrectal Needle Biopsy of the Prostate
TL;DR: Trimethoprim-sulfamethoxazole did not reduce the frequency of fever or bacteremia but did produce a significant reduction in bacteriuria, which was significant in men undergoing transrectal prostatic biopsies.
Journal ArticleDOI
Septic and crystalline joint disease. A simultaneous occurrence.
TL;DR: Bacteria and crystals were simultaneously recovered from the synovial fluid of two patients with acutely inflamed joints, and cause-and-effect relationship between these two types of arthritis cannot be established.
Journal ArticleDOI
Comparison of three transport systems for recovery of aerobes and anaerobes from wounds.
TL;DR: The three systems performed equally in the recovery of clinically significant pathogens from purulent clinical material, with essentially no difference among the three systems in the recoveries of aerobic or anaerobic organisms.
Journal ArticleDOI
Tuberculosis Management in the Mid-1970s
TL;DR: TUBERCULOSIS today is primarily an urban disease, with the lower-income population at greatest risk, and the American Thoracic Society has recommended that certain groups receive one year of isoniazid therapy.